Misplaced Pages

Cell-penetrating peptides (CPPs) are short peptides that facilitate cellular intake and uptake of molecules ranging from nanosize particles to small chemical compounds to large fragments of DNA. The "cargo" is associated with the peptides either through chemical linkage via covalent bonds or through non-covalent interactions.

CPPs deliver the cargo into cells, commonly through endocytosis, for use in research and medicine. Current use is limited by a lack of cell specificity in CPP-mediated cargo delivery and insufficient understanding of the modes of their uptake. Other delivery mechanisms that have been developed include CellSqueeze and electroporation.

CPPs typically have an amino acid composition that either contains a high relative abundance of positively charged amino acids such as lysine or arginine or has sequences that contain an alternating pattern of polar, charged amino acids and non-polar, hydrophobic amino acids. These two types of structures are referred to as polycationic or amphipathic, respectively. A third class of CPPs are the hydrophobic peptides, containing only apolar residues with low net charge or hydrophobic amino acid groups that are crucial for cellular uptake.

Transactivating transcriptional activator (TAT), from human immunodeficiency virus 1 (HIV-1), was the first CPP discovered. In 1988, two laboratories independently found that TAT could be efficiently taken up from the surrounding media by numerous cell types in culture. Since then, the number of known CPPs has expanded considerably, and small molecule synthetic analogues with more effective protein transduction properties have been generated.

A recent discovery found that Papillomaviridae, such as the human papillomavirus, use CPPs to penetrate the intracellular membrane to trigger retrograde trafficking of the viral unit to the nucleus.

Mechanisms of membrane translocation

Cell-penetrating peptides are of different sizes, amino acid sequences, and charges, but all CPPs have the ability to translocate the plasma membrane and facilitate the delivery of various molecular cargoes to the cytoplasm or an organelle. No real consensus explains the translocation mechanism, but candidates can be classified into three mechanisms: direct penetration in the membrane, endocytosis-mediated entry, and translocation through a transitory structure. CPP transduction is an area of ongoing research.

Cell-penetrating peptides (CPP) are able to transport different types of cargo molecules across plasma membrane; thus, they act as molecular delivery vehicles. They have numerous applications in medicine as drug delivery agents in the treatment of different diseases including cancer and virus inhibitors, as well as contrast agents for cell labeling. Examples of the latter include acting as a carrier for GFP, MRI contrast agents, or quantum dots.

Direct penetration

The majority of early research suggested that the translocation of polycationic CPPs across biological membranes occurred via an energy-independent cellular process. It was believed that translocation could progress at 4 °C and most likely involved a direct electrostatic interaction with negatively charged phospholipids. Researchers proposed several models in attempts to elucidate the biophysical mechanism of this energy-independent process. Although CPPs promote direct effects on the biophysical properties of pure membrane systems, the identification of fixation artifacts when using fluorescent labeled probe CPPs caused a reevaluation of CPP-import mechanisms. These studies promoted endocytosis as the translocation pathway. An example of direct penetration has been proposed for TAT. The first step in this proposed model is an interaction with the unfolded fusion protein (TAT) and the membrane through electrostatic interactions, which disrupt the membrane enough to allow the fusion protein to cross the membrane. After internalization, the fusion protein refolds due to the chaperone system. This mechanism was not agreed upon, and other mechanisms involving clathrin-dependent endocytosis have been suggested.

Many more detailed methods of CPP uptake have been proposed including transient pore formation. This mechanism involves strong interactions between cell-penetrating peptides and the phosphate groups on both sides of the lipid bilayer, the insertion of positively charged arginine side-chains that nucleate the formation of a transient pore, followed by the translocation of cell-penetrating peptides by diffusing on the pore surface. This mechanism explains how key ingredients, such as the cooperation among the peptides, the large positive charge, and specifically the guanidinium groups, contribute to the uptake. The proposed mechanism also illustrates the importance of membrane fluctuations. Indeed, mechanisms that involve large fluctuations of the membrane structure, such as transient pores and the insertion of charged amino acid side-chains, may be common and perhaps central to the functions of many membrane protein functions.

Endocytosis-mediated translocation

Endocytosis is the second mechanism liable for cellular internalization. Endocytosis is the process of cellular ingestion by which the plasma membrane folds inward to bring substances into the cell. During this process cells absorb material from the outside of the cell by imbibing it with their cell membrane. The classification of cellular localization using fluorescence or by endocytosis inhibitors is the basis of most examination. However, the procedure used during preparation of these samples creates questionable information regarding endocytosis. Moreover, studies show that cellular entry of penetratin by endocytosis is an energy-dependent process. This process is initiated by polyarginines interacting with heparan sulphates that promote endocytosis. Research has shown that TAT is internalized through a form of endocytosis called macropinocytosis.

Studies have illustrated that endocytosis is involved in the internalization of CPPs, but it has been suggested that different mechanisms could transpire at the same time. This is established by the behavior reported for penetratin and transportan wherein both membrane translocation and endocytosis occur concurrently.

Translocation through the formation of a transitory structure

The third mechanism responsible for the translocation is based on the formation of the inverted micelles. Inverted micelles are aggregates of colloidal surfactants in which the polar groups are concentrated in the interior and the lipophilic groups extend outward into the solvent. According to this model, a penetratin dimer combines with the negatively charged phospholipids, thus generating the formation of an inverted micelle inside of the lipid bilayer. The structure of the inverted micelles permits the peptide to remain in a hydrophilic environment. Nonetheless, this mechanism is still a matter of discussion, because the distribution of the penetratin between the inner and outer membrane is non-symmetric. This non-symmetric distribution produces an electrical field that has been well established. Increasing the amount of peptide on the outer leaflets causes the electric field to reach a critical value that can generate an electroporation-like event.

The last mechanism implied that internalization occurs by peptides that belong to the family of primary amphipathic peptides, MPG and Pep-1. Two similar models have been proposed based on physicochemical studies, consisting of circular dichroism, Fourier transform infrared, and nuclear magnetic resonance spectroscopy. These models are associated with electrophysiological measurements and investigations that have the ability to mimic model membranes such as monolayer at the air-water interface. The structure giving rise to the pores is the major difference between the proposed MPG and Pep-1 model. In the MPG model, the pore is formed by a b-barrel structure, whereas the Pep-1 is associated with helices. In addition, strong hydrophobic phospholipid-peptide interactions have been discovered in both models. In the two peptide models, the folded parts of the carrier molecule correlate to the hydrophobic domain, although the rest of the molecule remains unstructured.

Cell-penetrating peptide facilitated translocation is a topic of great debate. Evidence has been presented that translocation could use several different pathways for uptake. In addition, the mechanism of translocation can be dependent on whether the peptide is free or attached to cargo. The quantitative uptake of free or CPP connected to cargo can differ greatly but studies have not proven whether this change is a result of translocation efficiency or the difference in translocation pathway. It is probable that the results indicate that several CPP mechanisms are in competition and that several pathways contribute to CPP internalization.

Applications

Nucleic acid delivery

Nucleic acid-based macromolecules such as siRNA, antisense oligonucleotide, decoy DNA, and plasmid are promising biological and pharmacological therapeutics in regulation of gene expression. However, unlike other small-molecular drugs, their development and applications are limited by high molecular weight and negative charges, which results in poor uptake efficiency and low cellular traffic. To overcome these problems, several different delivery systems have been developed, including CPP-nucleic acid conjugate, which is a powerful tool.

Formation of CPP-nucleic acid complexes

Most CPP-nucleic acid complexes that have been proposed so far are formed through covalent bonding. A range of CPP-nucleic acid complexes have been synthesized through different chemistries that are either stable or cleavable linkages. And the most widely used method in publication is cleavable disulfide linkages through total stepwise solid-phase synthesis or solution-phase or solid-phase fragment coupling. Some other strategies like stable amide, thiazolidine, oxime and hydrazine linkage have also been developed. However, those covalent linking methods are limited by the concern that the synthetic covalent bond between CPP and nucleic acid may alter the biological activity of the latter. Thus, a new non-covalent strategy requiring no chemical modification with short amphipathic CPPs, like MPG and Pep-1 as carriers has been successfully applied for delivery of cargoes. These non-covalent conjugates are formed through either electrostatic or hydrophobic interactions. With this method, cargoes such as nucleic acids and proteins could be efficiently delivered while maintaining full biological activity.

siRNA delivery

Short interfering RNA (siRNA) is a powerful new tool that can interfere with and silence the expression of specific disease gene. To improve cellular uptake of siRNA, CPP strategies have been applied to facilitate the delivery of siRNA into cells through either covalent or non-covalent linkages. In one study, siRNA is covalently linked to transportan and penetratin by disulfide-linkage at 5'-end of the sense strands of siRNA to target luciferase or eGFP mRNA reporters. In another study, TAT-siRNA conjugate through a stable thiomaleimide linkage at 3'-end of siRNA was delivered into HeLa cells for eGFP gene silencing.

However, non-covalent strategies appear to be better for siRNA delivery with a more significant biological response. In one study, MPG/siRNA complexes formed through stable non-covalent strategy showed successful introduction of siRNA into cultured cells and induced robust regulation of target mRNA. Furthermore, MPG/siRNA complexes have also been applied for delivery of siRNA in vivo into mouse blastocytes for gene regulation. MPG forms stable complexes with siRNA with a low degradation rate and can be easily functionalized for specific targeting, which are major advantages compared with the covalent CPP technology.

New substrate design for siRNA delivery

siRNA cell delivery represent a valuable tool for treatment of cancer disease, viral infections and genetic disorders. However, classical strategies involve covalent linking of cargo molecules and CPPs, which does not provide efficient protection of siRNA molecules in vivo; thus results reported in literature are not consistent. Recently, non-covalent strategies have been successfully reported. Secondary amphipathic peptides based on aromatic tryptophan and arginine residues linked with lysine as spacer have been reported under the name of CADY. CADY contains a short peptide sequence of 20 amino acids, with the sequence “Ac-GLWRALWRLLRSLWRLLWRA-cysteamide." This peptide is able to self-assemble in a helical shape with hydrophilic and hydrophobic residues on different side of the molecule, it has two different orientations of the surface that represent the lowest energy and it is able to form complexes with siRNA at different molar ratio varying from 1:1 to 80:1. CADY is able to form a shield around siRNA molecule protecting it from biodegradative processes that may occur before cellular penetration occurs. These types of substrates may present important applications in vivo.

Antisense oligomer delivery

Antisense oligonucleotides (asONs) have been used in basic research and are being developed as possible medical treatments. CPP strategies have been developed to deliver antisense oligomers such as PNA and PMO into cells. Overcoming the repulsion by the cell membrane of negative-charged ONs and the degradation of asONs by enzymes, CPPs increase asONs bioavailability. Two types of neutral ON analogues, peptide nucleic acid (PNA) and phosphorodiamidate morpholino oligomers (PMO or Morpholino) are becoming dominant in this area. PNA has been conjugated with various CPPs either through disulfide linkages or through stable amide bonds. For example, antisense activity within cells that blocked expression of the galanin receptor was observed when a 21-mer PNA was coupled to the penetratin. Results on antiviral activity with PNA targeting HIV-1 have also been reported through disulfide linkage with TAT. CPP-PMO conjugates have also been successfully used to inhibit the replication of several viruses such as SARS and influenza and attachment of CPPs has improved the efficacy of splice-modifying Morpholinos in development for treatment of Duchenne muscular dystrophy

Decoy DNA delivery

Decoy DNA is an exogenous double-strand DNA (dsDNA), which can mimic a promoter sequence that can inhibit the activity of a specific transcription factor. But dsDNA has the same problem as other therapeutics, poor bioavailability. In one study, CPPs TP and TP10 were coupled to NFкB decoy DNA, which blocked the effect of interleukin-1-induced NFкB activation and IL-6 gene expression. In another study, TP10 coupled Myc decoy DNA decreased proliferative capacity of N2a cells.

Plasmid delivery

Individual genes can be inserted into specific sites on plasmids, and recombinant plasmids can be introduced into living cells. A method using macro-branched TAT has been proposed for plasmid DNA delivery into various cell lines and showed significant transfection capabilities. Multimers of TAT have been found to increase transfection efficiency of plasmid DNA by 6-8 times more than poly-L-arginine or mutant TAT2-M1, and by 390 times compared with the standard vectors.

Protein delivery

The development of therapeutic proteins that has presented a valuable method to treat diseases is limited by low efficiency of traditional delivery methods. The evaluation of cytosolic delivery of CPP linked proteins has been found to be prone to artifacts and therefore requires the use of evaluation methods that distinguish true cytosolic delivery from cell surface attached or endosomally entrapped CPP-proteins. Recently, several methods using CPPs as vehicles to deliver biologically active, full-length proteins into living cells and animals have been reported.

Several groups have successfully delivered CPP fused proteins in vitro. TAT was able to deliver different proteins, such as horseradish peroxidase and RNase A across cell membrane into the cytoplasm in different cell lines in vitro. The size range of proteins with effective delivery is from 30kDa to 120-150kDa. In one study, TAT-fused proteins are rapidly internalized by lipid raft−dependent macropinocytosis using a transducible TAT−Cre recombinase reporter assay on live cells. In another study, a TAT-fused protein was delivered into mitochondria of breast cancer cells and decreased the survival of breast cancer cells, which showed capability of TAT-fusion proteins to modulate mitochondrial function and cell survival. Moreover, cR10, a cyclic poly-arginine CPP, enabled the endocytose independent transduction of antigen binding proteins through the cellular membrane with immediate bioavailability. Thereby, the authors of the study were able to deliver fluorescent antigen binding proteins into cells facilitating live-cell immunostaining. However, few in vivo studies have succeeded. In one study, in vivo delivery of TAT- or penetratin-crosslinked Fab fragments yielded varied organ distributions and an overall increase in organ retention, which showed tissue localization.

A non-covalent method that forms CPP/protein complexes has also been developed to address the limitations in covalent methods, such as chemical modification before crosslinking, and denaturation of proteins before delivery. In one study, a short amphipathic peptide carrier, Pep-1, and protein complexes have proven effective for delivery. It was shown that Pep-1 could facilitate rapid cellular uptake of various peptides, proteins, and even full-length antibodies with high efficiency and less toxicity. This approach has greatly simplified the formulation of reagents.

Contrast agent transport

CPPs found applications as transporters of contrast agents across plasma membranes. These contrast agents are able to label the tumor cells, making the compounds important tools in cancer diagnosis; they are also used in in vivo and in vitro cellular experiments. The most important classes of CPP are isolated from viruses, such as TAT (transactivated-transcription) derived from HIV-1, penetratin, and transportan. The most widely used CPPs are based on TAT derivatives. TAT is an arginine-rich CPP. Several improvements for this substrate includes the usage of unnatural β or γ amino acids. This strategy offers multiple advantages, such resistance to proteolytic degradation, a natural degradation process by which peptide bonds are hydrolyzed to amino acids. Unnatural acid insertion in the peptide chain has multiple advantages. It facilitates the formation of stable foldamers with distinct secondary structure. β-Peptides are conformationally more stable in aqueous solution than naturally occurring peptides, especially for small chains. The secondary structure is reinforced by the presence of a rigid β-amino acid, which contains cyclohexane or cyclopentane fragments. These fragments generate a more rigid structure and influence the opening angle of the foldamer. These features are important for new peptide design. Helical β-peptides mimic antimicrobial activities of host defense peptides. This feature requires the orientation of cationic –hydrophilic on one side, and hydrophobic residues on the other side of the helix. The attachment of fluorescent group on one head of the molecule confers contrast properties. A new strategy to enhance the cellular up-take capacity of CPP is based on association of polycationic and polyanionic domains that are separated by a linker. Cellular association of polycationic residues (polyarginine) with negatively charged membrane cells is effectively blocked by the presence of polyanionic residue (poly-glutamic acid) and the linker, which confer the proper distance between these two charged residues in order to maximize their interaction. These peptides adopt hairpin structure, confirmed by overhauser effect correlation for proton-proton proximities of the two charged moieties. At this stage only the linker is exposed to protease hydrolysis in vivo applications. The linker hydrolysis occur and the two charged fragments experience more conformational freedom. In the absence of linker, the cationic peptide can interact more efficient with the target cell and cellular uptake occurs before proteolysis. This strategy found applications in labeling tumor cells in vivo. Tumor cells were marked in minutes. Linker degradation can be predicted by the amount of D-aminoacids (the unnatural isomer) incorporated in the peptide chain, this restricts in vivo proteolysis to the central linker.

Contrast agents as cargo molecules

Quantum dots

Quantum dots (QD) represent a relative new class of fluorescent probes that have superior optical properties than classical organic dyes based on fluorescent groups. The main advantages of QD include high quantum yields, broad absorption spectra, size-tunable emission spectra, and good resistance to chemical and photochemical degradation. In vivo tests have shown that several positively charged peptides (based on guanidine residues) are able to cross cell membranes and to promote cellular uptake of attached molecules including quantum dots. QD properties can be easily modified by changing the organic substrates linked to them, offering a versatile biological tool as cell markers. Research is in progress to optimize the methodologies for the intracellular delivery of QD and QD bioconjugates, and characterization of long-term in vivo photophysical properties.

Quantum dots are colloidal nanocrystals, based on a cadmium-selenium (CdSe) core covered with a zinc-sulfur (ZnS) layer. This substrate has been used intensively as a cellular marker because CdSe emits in the visible domain and is an excellent contrast agent, while the ZnS layer protects the core from oxidation and also the leeching of CdSe into the surrounding solution. This strategy also improves the photo-luminescence yield. The properties can be tuned by the thickness of the ZnS protective layers. Colloidal QD emission can be modulated from UV-Vis to the infrared by using different types of coating agents, such as ZnS, CdS, ZnSe, CdTe and PbSe. The properties of quantum dots can be also tuned by the synthetic scheme, high temperature solvent/ligand mixtures that influence the nanocrystal properties. High-quality QD contrast agents are obtained at elevated temperatures; however, because they have lower water solubility, their usage as cell markers is limited. Further functionalization with hydrophilic ligands is required.

The advantages of QD are represented by their fast action; they are able to label a target tissue or cell in seconds. In vivo studies show that QD are able to selectively label cancer cells, and they accumulate at tumor sites. Tumor cells labeled with QD can be tracked with multiphoton microscopy as they invade lung tissue. In both studies, spectral imaging and autofluorescent subtraction allowed multicolour in vivo visualization of cells and tissues. A major drawback of QD is their relatively high toxicity. Functionalizations with different substrates that increase bioaffinity and decrease toxicity are in progress. For instance, sulfur from the QD shell is able to form reversible disulfide bonds with a wide class of organic compounds.

Magnetic resonance imaging

Magnetic resonance imaging (MRI) is a powerful tool for disease diagnosis such as cancer metastasis and inflammation, using different metal chelates. Metal chelates increase the contrast signal between normal and diseased tissues by catalyzing the relaxation of water protons in their proximities. Typical examples are Gd3+ low-molecular-weight chelates, and superparamagnetic iron oxide (SPIO). In vivo administration of these agents allows the labeling of tumor cells; or cells can be labeled in vitro with contrast agents and then they can be injected and monitored in vivo by using MRI techniques.

SPIO nanoparticles confer high sensitivity in MRI but they have lower affinity for cells; they work at high concentrations. Functionalizations of these compounds using dendrimeric guanidines showed similar activities as TAT-based CPPs but higher toxicity. New substrates based on dendrons with hydroxyl or amine peripheries show low toxicity. Applications of SPIO includes cell labeling in vivo; due to low toxicity, they are clinically approved for use in liver, spleen, and gastrointestinal imaging.

The presence of octamer arginine residues allows cell membrane transduction of various cargo molecules including peptides, DNA, siRNA, and contrast agents. However, the ability of cross membrane is not unidirectional; arginine-based CPPs are able to enter-exit the cell membrane, displaying an overall decreasing concentration of contrast agent and a decrease of magnetic resonance (MR) signal in time. This limits their application in vivo. To solve this problem, contrast agents with disulfide, reversible bond between metal chelate and transduction moiety enhance the cell-associated retention. The disulfide bond is reduced by the target cell environment and the metal chelate remains trapped in the cytoplasm, increasing the retention time of chelate in the target cell.

References

1. ^ de Oliveira EC, Santana K, Josino L, Lima E, Lima AH, de Souza de Sales Júnior C (April 2021). "Predicting cell-penetrating peptides using machine learning algorithms and navigating in their chemical space". Scientific Reports. 11 (1): 7628. Bibcode:2021NatSR..11.7628D. doi:10.1038/s41598-021-87134-w. PMC 8027643. PMID 33828175.
2. Derakhshankhah H, Jafari S (December 2018). "Cell penetrating peptides: A concise review with emphasis on biomedical applications". Biomedicine & Pharmacotherapy. 108: 1090–1096. doi:10.1016/j.biopha.2018.09.097. PMID 30372809.
3. Milletti F (August 2012). "Cell-penetrating peptides: classes, origin, and current landscape". Drug Discovery Today. 17 (15–16): 850–60. doi:10.1016/j.drudis.2012.03.002. PMID 22465171.
4. Stalmans S, Wynendaele E, Bracke N, Gevaert B, D'Hondt M, Peremans K, Burvenich C, De Spiegeleer B (2013). "Chemical-functional diversity in cell-penetrating peptides". PLOS ONE. 8 (8): e71752. Bibcode:2013PLoSO...871752S. doi:10.1371/journal.pone.0071752. PMC 3739727. PMID 23951237.
5. Wagstaff KM, Jans DA (2006). "Protein transduction: cell penetrating peptides and their therapeutic applications". Current Medicinal Chemistry. 13 (12): 1371–87. doi:10.2174/092986706776872871. PMID 16719783.
6. Okuyama M, Laman H, Kingsbury SR, Visintin C, Leo E, Eward KL, Stoeber K, Boshoff C, Williams GH, Selwood DL (February 2007). "Small-molecule mimics of an alpha-helix for efficient transport of proteins into cells". Nature Methods. 4 (2): 153–9. doi:10.1038/nmeth997. PMID 17220893. S2CID 4675754.
7. Zhang P, Monteiro da Silva G, Deatherage C, Burd C, DiMaio D (September 2018). "Cell-Penetrating Peptide Mediates Intracellular Membrane Passage of Human Papillomavirus L2 Protein to Trigger Retrograde Trafficking". Cell. 174 (6): 1465–1476.e13. doi:10.1016/j.cell.2018.07.031. PMC 6128760. PMID 30122350.
8. Opalinska JB, Gewirtz AM (July 2002). "Nucleic-acid therapeutics: basic principles and recent applications". Nature Reviews. Drug Discovery. 1 (7): 503–14. doi:10.1038/nrd837. PMID 12120257. S2CID 37136826.
9. Eckstein F (July 2007). "The versatility of oligonucleotides as potential therapeutics". Expert Opinion on Biological Therapy. 7 (7): 1021–34. doi:10.1517/14712598.7.7.1021. PMID 17665991. S2CID 35816114.
10. Stewart KM, Horton KL, Kelley SO (July 2008). "Cell-penetrating peptides as delivery vehicles for biology and medicine". Organic & Biomolecular Chemistry. 6 (13): 2242–55. doi:10.1039/b719950c. PMID 18563254.
11. Luo D, Saltzman WM (January 2000). "Synthetic DNA delivery systems". Nature Biotechnology. 18 (1): 33–7. doi:10.1038/71889. PMID 10625387. S2CID 7068508.
12. Vivès E, Brodin P, Lebleu B (June 1997). "A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus". The Journal of Biological Chemistry. 272 (25): 16010–7. doi:10.1074/jbc.272.25.16010. PMID 9188504.
13. Zelphati O, Szoka FC (September 1996). "Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids". Pharmaceutical Research. 13 (9): 1367–72. doi:10.1023/a:1016026101195. PMID 8893276. S2CID 10646692.
14. Herce HD, Garcia AE (December 2007). "Molecular dynamics simulations suggest a mechanism for translocation of the HIV-1 TAT peptide across lipid membranes". Proceedings of the National Academy of Sciences of the United States of America. 104 (52): 20805–10. Bibcode:2007PNAS..10420805H. doi:10.1073/pnas.0706574105. PMC 2409222. PMID 18093956.
15. Herce HD, Garcia AE (December 2007). "Cell penetrating peptides: how do they do it?". Journal of Biological Physics. 33 (5–6): 345–56. doi:10.1007/s10867-008-9074-3. PMC 2565759. PMID 19669523.
16. Hu Y, Sinha SK, Patel S (June 2015). "Investigating Hydrophilic Pores in Model Lipid Bilayers Using Molecular Simulations: Correlating Bilayer Properties with Pore-Formation Thermodynamics". Langmuir. 31 (24): 6615–31. doi:10.1021/la504049q. PMC 4934177. PMID 25614183.
17. Hu Y, Liu X, Sinha SK, Patel S (March 2014). "Translocation thermodynamics of linear and cyclic nonaarginine into model DPPC bilayer via coarse-grained molecular dynamics simulation: implications of pore formation and nonadditivity". The Journal of Physical Chemistry B. 118 (10): 2670–82. doi:10.1021/jp412600e. PMC 3983342. PMID 24506488.
18. Hu Y, Patel S (August 2016). "Thermodynamics of cell-penetrating HIV1 TAT peptide insertion into PC/PS/CHOL model bilayers through transmembrane pores: the roles of cholesterol and anionic lipids". Soft Matter. 12 (32): 6716–27. Bibcode:2016SMat...12.6716H. doi:10.1039/C5SM01696G. PMID 27435187.
19. Frankel AD, Pabo CO (December 1988). "Cellular uptake of the tat protein from human immunodeficiency virus". Cell. 55 (6): 1189–93. doi:10.1016/0092-8674(88)90263-2. PMID 2849510.
20. Lundberg M, Johansson M (August 2001). "Is VP22 nuclear homing an artifact?". Nature Biotechnology. 19 (8): 713–4. doi:10.1038/90741. PMID 11479552.
21. Lundberg M, Wikström S, Johansson M (July 2003). "Cell surface adherence and endocytosis of protein transduction domains". Molecular Therapy. 8 (1): 143–50. doi:10.1016/s1525-0016(03)00135-7. PMID 12842437.
22. Howl J, Nicholl ID, Jones S (August 2007). "The many futures for cell-penetrating peptides: how soon is now?". Biochemical Society Transactions. 35 (Pt 4): 767–9. doi:10.1042/bst0350767. hdl:2436/29794. PMID 17635144.
23. Plénat T, Deshayes S, Boichot S, Milhiet PE, Cole RB, Heitz F, Le Grimellec C (October 2004). "Interaction of primary amphipathic cell-penetrating peptides with phospholipid-supported monolayers". Langmuir. 20 (21): 9255–61. doi:10.1021/la048622b. PMID 15461515.
24. Deshayes S, Gerbal-Chaloin S, Morris MC, Aldrian-Herrada G, Charnet P, Divita G, Heitz F (December 2004). "On the mechanism of non-endosomial peptide-mediated cellular delivery of nucleic acids". Biochimica et Biophysica Acta (BBA) - Biomembranes. 1667 (2): 141–7. doi:10.1016/j.bbamem.2004.09.010. PMID 15581849.
25. Deshayes S, Heitz A, Morris MC, Charnet P, Divita G, Heitz F (February 2004). "Insight into the mechanism of internalization of the cell-penetrating carrier peptide Pep-1 through conformational analysis". Biochemistry. 43 (6): 1449–57. doi:10.1021/bi035682s. PMID 14769021.
26. Magzoub M, Kilk K, Eriksson LE, Langel U, Gräslund A (May 2001). "Interaction and structure induction of cell-penetrating peptides in the presence of phospholipid vesicles". Biochimica et Biophysica Acta (BBA) - Biomembranes. 1512 (1): 77–89. doi:10.1016/s0005-2736(01)00304-2. PMID 11334626.
27. Deshayes S, Plénat T, Aldrian-Herrada G, Divita G, Le Grimellec C, Heitz F (June 2004). "Primary amphipathic cell-penetrating peptides: structural requirements and interactions with model membranes". Biochemistry. 43 (24): 7698–706. doi:10.1021/bi049298m. PMID 15196012.
28. Derossi D, Calvet S, Trembleau A, Brunissen A, Chassaing G, Prochiantz A (July 1996). "Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent". The Journal of Biological Chemistry. 271 (30): 18188–93. doi:10.1074/jbc.271.30.18188. PMID 8663410.
29. Tilstra J, Rehman KK, Hennon T, Plevy SE, Clemens P, Robbins PD (August 2007). "Protein transduction: identification, characterization and optimization". Biochemical Society Transactions. 35 (Pt 4): 811–5. doi:10.1042/bst0350811. PMID 17635154.
30. Morris M, Deshayes S, Simeoni F, Aldrian-Herrada G, Heitz F, Divita G (2006). "A Noncovalent Peptide-Based Strategy for Peptide and Short Interfering RNA Delivery". Handbook of Cell-Penetrating Peptides, Second Edition. Pharmacology and Toxicology: Basic and Clinical Aspects. Vol. 20061339. pp. 387–408. doi:10.1201/9781420006087.ch22 (inactive 2024-11-11). ISBN 978-0-8493-5090-0.{{cite book}}: CS1 maint: DOI inactive as of November 2024 (link)
31. El-Andaloussi S, Holm T, Langel U (2005). "Cell-penetrating peptides: mechanisms and applications". Current Pharmaceutical Design. 11 (28): 3597–611. doi:10.2174/138161205774580796. PMID 16305497.
32. Gariépy J, Kawamura K (January 2001). "Vectorial delivery of macromolecules into cells using peptide-based vehicles". Trends in Biotechnology. 19 (1): 21–8. doi:10.1016/s0167-7799(00)01520-1. PMID 11146099.
33. Turner J, Arzumanov A, Ivanova G, Fabani M, Gait M (2006). "Peptide Conjugates of Oligonucleotide Analogs and siRNA for Gene Expression Modulation". Handbook of Cell-Penetrating Peptides, Second Edition. Pharmacology and Toxicology: Basic and Clinical Aspects. Vol. 20061339. pp. 313–328. doi:10.1201/9781420006087.ch18 (inactive 2024-11-11). ISBN 978-0-8493-5090-0.{{cite book}}: CS1 maint: DOI inactive as of November 2024 (link)
34. Stetsenko DA, Gait MJ (August 2000). "Efficient conjugation of peptides to oligonucleotides by "native ligation"". The Journal of Organic Chemistry. 65 (16): 4900–8. doi:10.1021/jo000214z. PMID 10956469.
35. Meade BR, Dowdy SF (March 2007). "Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides". Advanced Drug Delivery Reviews. 59 (2–3): 134–40. doi:10.1016/j.addr.2007.03.004. PMID 17451840.
36. Morris MC, Vidal P, Chaloin L, Heitz F, Divita G (July 1997). "A new peptide vector for efficient delivery of oligonucleotides into mammalian cells". Nucleic Acids Research. 25 (14): 2730–6. doi:10.1093/nar/25.14.2730. PMC 146800. PMID 9207018.
37. ^ Simeoni F, Morris MC, Heitz F, Divita G (June 2003). "Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells". Nucleic Acids Research. 31 (11): 2717–24. doi:10.1093/nar/gkg385. PMC 156720. PMID 12771197.
38. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J (June 2007). "Interfering with disease: a progress report on siRNA-based therapeutics". Nature Reviews. Drug Discovery. 6 (6): 443–53. doi:10.1038/nrd2310. PMC 7098199. PMID 17541417.
39. Muratovska A, Eccles MR (January 2004). "Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells". FEBS Letters. 558 (1–3): 63–8. doi:10.1016/s0014-5793(03)01505-9. PMID 14759517. S2CID 22288046.
40. Chiu YL, Ali A, Chu CY, Cao H, Rana TM (August 2004). "Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells". Chemistry & Biology. 11 (8): 1165–75. doi:10.1016/j.chembiol.2004.06.006. PMID 15324818.
41. Zeineddine D, Papadimou E, Chebli K, Gineste M, Liu J, Grey C, Thurig S, Behfar A, Wallace VA, Skerjanc IS, Pucéat M (October 2006). "Oct-3/4 dose dependently regulates specification of embryonic stem cells toward a cardiac lineage and early heart development". Developmental Cell. 11 (4): 535–46. doi:10.1016/j.devcel.2006.07.013. PMID 17011492.
42. Crombez L, Aldrian-Herrada G, Konate K, Nguyen QN, McMaster GK, Brasseur R, Heitz F, Divita G (January 2009). "A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells". Molecular Therapy. 17 (1): 95–103. doi:10.1038/mt.2008.215. PMC 2834975. PMID 18957965.
43. Zatsepin TS, Turner JJ, Oretskaya TS, Gait MJ (2005). "Conjugates of oligonucleotides and analogues with cell penetrating peptides as gene silencing agents". Current Pharmaceutical Design. 11 (28): 3639–54. doi:10.2174/138161205774580769. PMID 16305500.
44. Pooga M, Soomets U, Hällbrink M, Valkna A, Saar K, Rezaei K, et al. (September 1998). "Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo". Nature Biotechnology. 16 (9): 857–61. doi:10.1038/nbt0998-857. PMID 9743120. S2CID 30222490.
45. Tripathi S, Chaubey B, Barton BE, Pandey VN (June 2007). "Anti HIV-1 virucidal activity of polyamide nucleic acid-membrane transducing peptide conjugates targeted to primer binding site of HIV-1 genome". Virology. 363 (1): 91–103. doi:10.1016/j.virol.2007.01.016. PMC 2038983. PMID 17320140.
46. Neuman BW, Stein DA, Kroeker AD, Moulton HM, Bestwick RK, Iversen PL, Buchmeier MJ (2006). "Inhibition and escape of SARS-CoV treated with antisense morpholino oligomers". The Nidoviruses. Advances in Experimental Medicine and Biology. Vol. 581. pp. 567–71. doi:10.1007/978-0-387-33012-9_103. ISBN 978-0-387-26202-4. PMC 7123819. PMID 17037599.
47. Ge Q, Pastey M, Kobasa D, Puthavathana P, Lupfer C, Bestwick RK, et al. (November 2006). "Inhibition of multiple subtypes of influenza A virus in cell cultures with morpholino oligomers". Antimicrobial Agents and Chemotherapy. 50 (11): 3724–33. doi:10.1128/aac.00644-06. PMC 1635187. PMID 16966399.
48. Wu B, Moulton HM, Iversen PL, Jiang J, Li J, Li J, et al. (September 2008). "Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer". Proceedings of the National Academy of Sciences of the United States of America. 105 (39): 14814–9. Bibcode:2008PNAS..10514814W. doi:10.1073/pnas.0805676105. PMC 2546441. PMID 18806224.
49. Morishita R, Gibbons GH, Horiuchi M, Ellison KE, Nakama M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ (June 1995). "A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo". Proceedings of the National Academy of Sciences of the United States of America. 92 (13): 5855–9. Bibcode:1995PNAS...92.5855M. doi:10.1073/pnas.92.13.5855. PMC 41600. PMID 7597041.
50. Fisher L, Soomets U, Cortés Toro V, Chilton L, Jiang Y, Langel U, Iverfeldt K (August 2004). "Cellular delivery of a double-stranded oligonucleotide NFkappaB decoy by hybridization to complementary PNA linked to a cell-penetrating peptide". Gene Therapy. 11 (16): 1264–72. doi:10.1038/sj.gt.3302291. PMID 15292915.
51. El-Andaloussi S, Johansson H, Magnusdottir A, Järver P, Lundberg P, Langel U (December 2005). "TP10, a delivery vector for decoy oligonucleotides targeting the Myc protein". Journal of Controlled Release. 110 (1): 189–201. doi:10.1016/j.jconrel.2005.09.012. PMID 16253378.
52. Liu Z, Li M, Cui D, Fei J (February 2005). "Macro-branched cell-penetrating peptide design for gene delivery". Journal of Controlled Release. 102 (3): 699–710. doi:10.1016/j.jconrel.2004.10.013. PMID 15681091.
53. Rudolph C, Plank C, Lausier J, Schillinger U, Müller RH, Rosenecker J (March 2003). "Oligomers of the arginine-rich motif of the HIV-1 TAT protein are capable of transferring plasmid DNA into cells". The Journal of Biological Chemistry. 278 (13): 11411–8. doi:10.1074/jbc.m211891200. PMID 12519756.
54. Richard JP, Melikov K, Vives E, Ramos C, Verbeure B, Gait MJ, Chernomordik LV, Lebleu B (January 2003). "Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake". The Journal of Biological Chemistry. 278 (1): 585–90. doi:10.1074/jbc.M209548200. PMID 12411431.
55. Marschall AL, Zhang C, Frenzel A, Schirrmann T, Hust M, Perez F, Dübel S (2014). "Delivery of antibodies to the cytosol: debunking the myths". mAbs. 6 (4): 943–56. doi:10.4161/mabs.29268. PMC 4171028. PMID 24848507.
56. Marschall AL, Zhang C, Dübel S (2017). "Evaluating the Delivery of Proteins to the Cytosol of Mammalian Cells". Cancer Gene Networks. Methods in Molecular Biology. Vol. 1513. pp. 201–208. doi:10.1007/978-1-4939-6539-7_14. ISBN 978-1-4939-6537-3. PMID 27807839.
57. Wadia JS, Stan RV, Dowdy SF (March 2004). "Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis". Nature Medicine. 10 (3): 310–5. doi:10.1038/nm996. PMID 14770178. S2CID 21545515.
58. Herce HD, Schumacher D, Schneider AF, Ludwig AK, Mann FA, Fillies M, Kasper MA, Reinke S, Krause E, Leonhardt H, Cardoso MC, Hackenberger CP (August 2017). "Cell-permeable nanobodies for targeted immunolabelling and antigen manipulation in living cells". Nature Chemistry. 9 (8): 762–771. Bibcode:2017NatCh...9..762H. doi:10.1038/nchem.2811. PMID 28754949.
59. Kameyama S, Horie M, Kikuchi T, Omura T, Takeuchi T, Nakase I, Sugiura Y, Futaki S (2006). "Effects of cell-permeating peptide binding on the distribution of 125I-labeled Fab fragment in rats". Bioconjugate Chemistry. 17 (3): 597–602. doi:10.1021/bc050258k. PMID 16704196.
60. Morris MC, Depollier J, Mery J, Heitz F, Divita G (December 2001). "A peptide carrier for the delivery of biologically active proteins into mammalian cells". Nature Biotechnology. 19 (12): 1173–6. doi:10.1038/nbt1201-1173. PMID 11731788. S2CID 24743283.
61. Cheng RP, Gellman SH, DeGrado WF (October 2001). "beta-Peptides: from structure to function". Chemical Reviews. 101 (10): 3219–32. doi:10.1021/cr000045i. PMID 11710070.
62. Seebach D, Abele S, Schreiber JV, Martinoni B, Nussbaum AK, Schild H, Schulz H, Hennecke H, Woessner R, Bitsch F (December 1998). "Biological and pharmacokinetic studies with β-peptides". CHIMIA International Journal for Chemistry. 52 (12): 734–9. doi:10.2533/chimia.1998.734. S2CID 248509644.
63. Akkarawongsa R, Potocky TB, English EP, Gellman SH, Brandt CR (June 2008). "Inhibition of herpes simplex virus type 1 infection by cationic beta-peptides". Antimicrobial Agents and Chemotherapy. 52 (6): 2120–9. doi:10.1128/AAC.01424-07. PMC 2415802. PMID 18391029.
64. Tew GN, Liu D, Chen B, Doerksen RJ, Kaplan J, Carroll PJ, Klein ML, DeGrado WF (April 2002). "De novo design of biomimetic antimicrobial polymers". Proceedings of the National Academy of Sciences of the United States of America. 99 (8): 5110–4. doi:10.1073/pnas.082046199. PMC 122730. PMID 11959961.
65. Porter EA, Weisblum B, Gellman SH (June 2002). "Mimicry of host-defense peptides by unnatural oligomers: antimicrobial beta-peptides". Journal of the American Chemical Society. 124 (25): 7324–30. doi:10.1021/ja0260871. PMID 12071741.
66. Raguse TL, Porter EA, Weisblum B, Gellman SH (October 2002). "Structure-activity studies of 14-helical antimicrobial beta-peptides: probing the relationship between conformational stability and antimicrobial potency". Journal of the American Chemical Society. 124 (43): 12774–85. doi:10.1021/ja0270423. PMID 12392424.
67. Grdisa M (2011). "The delivery of biologically active (therapeutic) peptides and proteins into cells". Current Medicinal Chemistry. 18 (9): 1373–9. doi:10.2174/092986711795029591. PMID 21366527.
68. Gammon ST, Villalobos VM, Prior JL, Sharma V, Piwnica-Worms D (2003). "Quantitative analysis of permeation peptide complexes labeled with Technetium-99m: chiral and sequence-specific effects on net cell uptake". Bioconjugate Chemistry. 14 (2): 368–76. doi:10.1021/bc0256291. PMID 12643747.
69. Polyakov V, Sharma V, Dahlheimer JL, Pica CM, Luker GD, Piwnica-Worms D (2000). "Novel Tat-peptide chelates for direct transduction of technetium-99m and rhenium into human cells for imaging and radiotherapy". Bioconjugate Chemistry. 11 (6): 762–71. doi:10.1021/bc000008y. PMID 11087323.
70. Jiang T, Olson ES, Nguyen QT, Roy M, Jennings PA, Tsien RY (December 2004). "Tumor imaging by means of proteolytic activation of cell-penetrating peptides". Proceedings of the National Academy of Sciences of the United States of America. 101 (51): 17867–72. Bibcode:2004PNAS..10117867J. doi:10.1073/pnas.0408191101. PMC 539314. PMID 15601762.
71. Delehanty JB, Medintz IL, Pons T, Brunel FM, Dawson PE, Mattoussi H (2006). "Self-assembled quantum dot-peptide bioconjugates for selective intracellular delivery". Bioconjugate Chemistry. 17 (4): 920–7. doi:10.1021/bc060044i. PMC 2519024. PMID 16848398.
72. Alivisatos AP, Gu W, Larabell C (2005). "Quantum dots as cellular probes". Annual Review of Biomedical Engineering. 7: 55–76. doi:10.1146/annurev.bioeng.7.060804.100432. PMID 16004566.
73. ^ Medintz IL, Uyeda HT, Goldman ER, Mattoussi H (June 2005). "Quantum dot bioconjugates for imaging, labelling and sensing". Nature Materials. 4 (6): 435–46. Bibcode:2005NatMa...4..435M. doi:10.1038/nmat1390. PMID 15928695. S2CID 13737788.
74. Parak WJ, Gerion D, Pellegrino T, Zanchet D, Micheel C, Williams SC, Boudreau R, Le Gros MA, Larabell CA, Alivisatos AP (June 2003). "Biological applications of colloidal nanocrystals". Nanotechnology. 14 (7): R15–R27. doi:10.1088/0957-4484/14/7/201. S2CID 56211942.
75. Parak WJ, Pellegrino T, Plank C (February 2005). "Labelling of cells with quantum dots". Nanotechnology. 16 (2): R9–R25. doi:10.1088/0957-4484/16/2/R01. PMID 21727419. S2CID 32135690.
76. Dabbousi BO, Rodriguez-Viejo J, Mikulec FV, Heine JR, Mattoussi H, Ober R, Jensen KF, Bawendi MG (November 1997). "(CdSe) ZnS core− shell quantum dots: synthesis and characterization of a size series of highly luminescent nanocrystallites". The Journal of Physical Chemistry B. 101 (46): 9463–75. doi:10.1021/jp971091y.
77. Gao X, Cui Y, Levenson RM, Chung LW, Nie S (August 2004). "In vivo cancer targeting and imaging with semiconductor quantum dots". Nature Biotechnology. 22 (8): 969–76. doi:10.1038/nbt994. PMID 15258594. S2CID 41561027.
78. Bulte JW, Douglas T, Witwer B, Zhang SC, Strable E, Lewis BK, Zywicke H, Miller B, van Gelderen P, Moskowitz BM, Duncan ID, Frank JA (December 2001). "Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells". Nature Biotechnology. 19 (12): 1141–7. doi:10.1038/nbt1201-1141. PMID 11731783. S2CID 24939068.
79. Pittet MJ, Swirski FK, Reynolds F, Josephson L, Weissleder R (2006). "Labeling of immune cells for in vivo imaging using magnetofluorescent nanoparticles". Nature Protocols. 1 (1): 73–9. doi:10.1038/nprot.2006.11. PMID 17406214. S2CID 13008755.
80. Foster PJ, Dunn EA, Karl KE, Snir JA, Nycz CM, Harvey AJ, Pettis RJ (March 2008). "Cellular magnetic resonance imaging: in vivo imaging of melanoma cells in lymph nodes of mice". Neoplasia. 10 (3): 207–16. doi:10.1593/neo.07937. PMC 2259450. PMID 18320065.
81. Martin AL, Bernas LM, Rutt BK, Foster PJ, Gillies ER (December 2008). "Enhanced cell uptake of superparamagnetic iron oxide nanoparticles functionalized with dendritic guanidines". Bioconjugate Chemistry. 19 (12): 2375–84. doi:10.1021/bc800209u. PMID 19053308.
82. Allen MJ, MacRenaris KW, Venkatasubramanian PN, Meade TJ (March 2004). "Cellular delivery of MRI contrast agents". Chemistry & Biology. 11 (3): 301–7. doi:10.1016/j.chembiol.2004.03.003. PMID 15123259.
83. Futaki S (February 2005). "Membrane-permeable arginine-rich peptides and the translocation mechanisms". Advanced Drug Delivery Reviews. 57 (4): 547–58. doi:10.1016/j.addr.2004.10.009. PMID 15722163.
84. Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, Ueda K, Sugiura Y (February 2001). "Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery". The Journal of Biological Chemistry. 276 (8): 5836–40. doi:10.1074/jbc.M007540200. PMID 11084031.
85. Endres PJ, MacRenaris KW, Vogt S, Meade TJ (October 2008). "Cell-permeable MR contrast agents with increased intracellular retention". Bioconjugate Chemistry. 19 (10): 2049–59. doi:10.1021/bc8002919. PMC 2650427. PMID 18803414.

• Peptides
• Cell biology